
Nyxoah Partners with ResMed Germany to Advance Obstructive Sleep Apnea (OSA) Awareness and Therapy
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company specializing in innovative solutions for the treatment of Obstructive Sleep Apnea (OSA), has announced a strategic partnership with ResMed Germany. This collaboration aims to enhance awareness of OSA and improve therapy access and penetration within the German market. Over 95 percent of patients in Germany suffering from sleep apnea are not diagnosed or treated. Both Nyxoah and ResMed are market leaders in manufacturing and selling products for OSA. ResMed is a leader in continuous positive airway pressure (CPAP) devices and Nyxoah markets the Genio system outside the United States. Genio operates by stimulating the hypoglossal nerve, responsible for controlling tongue movement. This stimulation prevents the tongue from collapsing backward and obstructing the upper airway during sleep, a common issue in OSA. The device is surgically implanted in the chin and is an alternative to CPAP therapy for patients who may struggle with compliance or adherence.
Together, Nyxoah and ResMed Germany will create a comprehensive continuum of care designed to guide OSA patients in Germany from diagnosis to treatment. This initiative includes several key components:
1. OSA Helplines and Direct-to-Consumer Marketing Initiatives: By establishing OSA helplines and consumer-focused marketing campaigns, the partnership aims to raise awareness and facilitate access to information and resources for individuals affected by OSA.
2. Sales and Marketing Efforts Targeting ENTs and Sleep Physicians: Nyxoah and ResMed Germany will collaborate on sales and marketing strategies aimed at healthcare professionals specializing in ear, nose, and throat (ENT) and sleep medicine. This approach seeks to ensure that medical practitioners are well-informed about the latest OSA treatment options.
3. Patient and Clinician Educational Programs and Symposiums: The partnership will organize educational programs and symposiums to provide patients and healthcare providers with the knowledge they need to make informed decisions regarding OSA treatment. These initiatives will help patients understand their therapy options, including mandibular devices, continuous positive airway pressure (CPAP), and hypoglossal nerve stimulation (HGNS).
Olivier Taelman, Nyxoah’s Chief Executive Officer, expressed enthusiasm for the collaboration, emphasizing the patient-centric approach: “We are thrilled to partner with ResMed Germany, as it strengthens further our patient-first approach to treating obstructive sleep apnea. OSA reduces quality of life and can result in other serious medical conditions, such as cardiovascular disease, and type 2 diabetes. Together, ResMed Germany and Nyxoah will heighten awareness of OSA and increase therapy penetration.”